Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bioequivalence Study of BGM0504 Injection
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Summary
This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).
Official title: A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2025-12-23
Completion Date
2026-02-12
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
BGM0504 Injection multi-dose pen
5 mg, single subcutaneous injection in the abdominal region
BGM0504 Injection single-dose pen
5 mg, single subcutaneous injection in the abdominal region
BGM0504 Injection single-dose pen
5 mg, single subcutaneous injection in the abdominal region
Locations (1)
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China